isradipine has been researched along with Disease Exacerbation in 14 studies
Isradipine: A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The isradipine dose may have been insufficient to engage the target calcium channels associated with neuroprotective effects." | 6.94 | Isradipine Versus Placebo in Early Parkinson Disease: A Randomized Trial. ( , 2020) |
| "Isradipine is a dihydropyridine calcium channel inhibitor that has demonstrated concentration-dependent neuroprotective effects in animal models of Parkinson's disease (PD) but failed to show efficacy in a phase 3 clinical trial." | 3.01 | Isradipine plasma pharmacokinetics and exposure-response in early Parkinson's disease. ( James Surmeier, D; Javidnia, M; Oakes, D; Simuni, T; Venuto, CS; Yang, L, 2021) |
| "The isradipine dose may have been insufficient to engage the target calcium channels associated with neuroprotective effects." | 2.94 | Isradipine Versus Placebo in Early Parkinson Disease: A Randomized Trial. ( , 2020) |
| "Sixty patients with chronic renal failure and hypertension were enrolled in the study." | 2.70 | A randomized and double-blind comparison of isradipine and spirapril as monotherapy and in combination on the decline in renal function in patients with chronic renal failure and hypertension. ( Jensen, HA; Ladefoged, SD; Mehlsen, J; Møller, ML; Petersen, JR; Petersen, LJ; Talleruphuus, U, 2001) |
| "Parkinson's disease is a disabling hypokinetic neurological movement disorder in which the aetiology is unknown in the majority of cases." | 2.53 | Calcium Channel Antagonists as Disease-Modifying Therapy for Parkinson's Disease: Therapeutic Rationale and Current Status. ( Hurley, MJ; Swart, T, 2016) |
| "Treatment with isradipine prevented against MPP+-induced iron influx in the MES23." | 1.46 | Isradipine attenuates MPTP-induced dopamine neuron degeneration by inhibiting up-regulation of L-type calcium channels and iron accumulation in the substantia nigra of mice. ( Liu, S; Ma, ZG; Wang, QM; Xu, YY, 2017) |
| "Sepsis was induced by cecal ligation and puncture (CLP)." | 1.34 | Intracellular redistribution of dihydropyridine receptor in the rat heart during the progression of sepsis. ( Hsu, C; Hsu, HK; Liu, MS; Tang, C; Wu, G; Yang, RC; Yang, SL, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 5 (35.71) | 2.80 |
| Authors | Studies |
|---|---|
| Surmeier, DJ | 1 |
| Nguyen, JT | 1 |
| Lancki, N | 1 |
| Venuto, CS | 2 |
| Oakes, D | 2 |
| Simuni, T | 2 |
| Wyse, RK | 1 |
| Maiti, B | 1 |
| Perlmutter, JS | 1 |
| Yang, L | 1 |
| Javidnia, M | 1 |
| James Surmeier, D | 1 |
| Wang, QM | 1 |
| Xu, YY | 1 |
| Liu, S | 1 |
| Ma, ZG | 1 |
| Swart, T | 1 |
| Hurley, MJ | 1 |
| Shangina, OA | 1 |
| Kostin, VI | 1 |
| Koturga, LI | 1 |
| Hsu, C | 1 |
| Wu, G | 1 |
| Yang, SL | 1 |
| Hsu, HK | 1 |
| Yang, RC | 1 |
| Tang, C | 1 |
| Liu, MS | 1 |
| Futrakul, P | 1 |
| Futrakul, N | 1 |
| Sitprija, V | 1 |
| Sensirivatana, R | 1 |
| Watana, D | 1 |
| Kingwatanakul, P | 1 |
| Borhani, NO | 1 |
| Mercuri, M | 1 |
| Borhani, PA | 1 |
| Buckalew, VM | 1 |
| Canossa-Terris, M | 1 |
| Carr, AA | 1 |
| Kappagoda, T | 1 |
| Rocco, MV | 1 |
| Schnaper, HW | 1 |
| Sowers, JR | 1 |
| Bond, MG | 1 |
| Maher, MJ | 1 |
| Dworkin, LD | 1 |
| Strauer, BE | 1 |
| Schwartzkopff, B | 1 |
| Petersen, LJ | 1 |
| Petersen, JR | 1 |
| Talleruphuus, U | 1 |
| Møller, ML | 1 |
| Ladefoged, SD | 1 |
| Mehlsen, J | 1 |
| Jensen, HA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease[NCT02168842] | Phase 3 | 336 participants (Actual) | Interventional | 2014-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the adjusted UPDRS Score in the active treatment arm versus placebo between the baseline and 36 month visit. The change of adjusted UPDRS ranges from -100 to 150, larger value shows more disability from PD. (NCT02168842)
Timeframe: Baseline to 36 months of treatment
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Isradipine | 13.49 |
| Placebo (for Isradipine) | 13.85 |
Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the Ambulatory Capacity in the active treatment arm versus placebo between the baseline and 36 month visit. The change in Ambulatory Capacity ranges from -4 to 12, larger value shows worsening of conditions. (NCT02168842)
Timeframe: Baseline to 36 months of treatment
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Isradipine | 0.59 |
| Placebo (for Isradipine) | 0.50 |
Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the BDI Total Score in the active treatment arm versus placebo between the baseline and 36 month visit. The change in BDI Total Score ranges from -9 to 22, larger value shows worsening of conditions. (NCT02168842)
Timeframe: Baseline to 36 months of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Isradipine | 0.77 |
| Placebo (for Isradipine) | 1.34 |
Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the Diastolic BP, Seated in the active treatment arm versus placebo between the baseline and 36 month visit. The change in Diastolic BP, Seated ranges from -35 to 25. larger value shows worsening of conditions. (NCT02168842)
Timeframe: Baseline to 36 months of treatment
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Isradipine | -4.64 |
| Placebo (for Isradipine) | -0.71 |
Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the H/Y Stage in the active treatment arm versus placebo between the baseline and 36 month visit. The change in H/Y Stage ranges from -1 to 3, larger value shows worsening of conditions. (NCT02168842)
Timeframe: Baseline to 36 months of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Isradipine | 0.15 |
| Placebo (for Isradipine) | 0.21 |
Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the LED(levodopa equivalent dose) in the active treatment arm versus placebo between the baseline and 36 month visit. The change of LED ranges from -100 to 3000, larger value shows more disability from PD. (NCT02168842)
Timeframe: Baseline to 36 months of treatment
| Intervention | mg (Least Squares Mean) |
|---|---|
| Isradipine | 389 |
| Placebo (for Isradipine) | 375 |
Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the LED(levodopa equivalent dose) cumulative in the active treatment arm versus placebo between the baseline and 36 month visit. The change of LED cumulative ranges from 0 to 1200000, larger value shows more disability from PD. (NCT02168842)
Timeframe: Baseline to 36 months of treatment
| Intervention | mg (Least Squares Mean) |
|---|---|
| Isradipine | 676 |
| Placebo (for Isradipine) | 697 |
Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the Levodopa in the active treatment arm versus placebo between the baseline and 36 month visit. The change of LED ranges from -200 to 2000, larger value shows more disability from PD. (NCT02168842)
Timeframe: Baseline to 36 months of treatment
| Intervention | mg (Least Squares Mean) |
|---|---|
| Isradipine | 307 |
| Placebo (for Isradipine) | 307 |
Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the Levodopa Cumulative in the active treatment arm versus placebo between the baseline and 36 month visit. The change of Levodopa cumulative ranges from 0 to 800000, larger value shows more disability from PD. (NCT02168842)
Timeframe: Baseline to 36 months of treatment
| Intervention | mg (Least Squares Mean) |
|---|---|
| Isradipine | 471 |
| Placebo (for Isradipine) | 508 |
Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the MDS-UPDRS mEDL(Motor Experiences of Daily Living) in the active treatment arm versus placebo between the baseline and 36 month visit. The change in MDS-UPDRS mEDL ranges from -8 to 35, larger value shows more disability from PD. (NCT02168842)
Timeframe: Baseline to 36 months of treatment
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Isradipine | 2.32 |
| Placebo (for Isradipine) | 2.57 |
Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the MDS-UPDRS nmEDL(Non-Motor Experiences of Daily Living) in the active treatment arm versus placebo between the baseline and 36 month visit. The change in MDS-UPDRS nmEDL ranges from -6 to 10, larger value shows more disability from PD. (NCT02168842)
Timeframe: Baseline to 36 months of treatment
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Isradipine | 1.93 |
| Placebo (for Isradipine) | 1.76 |
Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the MoCA Score in the active treatment arm versus placebo between the baseline and 36 month visit. The change in MoCA Score ranges from -10 to 6, larger value shows improvement of conditions. (NCT02168842)
Timeframe: Baseline to 36 months of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Isradipine | -0.04 |
| Placebo (for Isradipine) | -0.07 |
Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the Modified Rankin Score in the active treatment arm versus placebo between the baseline and 36 month visit. The change in Modified Rankin Score ranges from -1 to 3, larger value shows worsening of conditions. (NCT02168842)
Timeframe: Baseline to 36 months of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Isradipine | 0.18 |
| Placebo (for Isradipine) | 0.29 |
Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the PDQ39 Total Score in the active treatment arm versus placebo between the baseline and 36 month visit. The change in PDQ39 Total Score ranges from -16 to 44, larger value shows worsening of conditions. (NCT02168842)
Timeframe: Baseline to 36 months of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Isradipine | 2.80 |
| Placebo (for Isradipine) | 3.42 |
Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the SE/ADL in the active treatment arm versus placebo between the baseline and 36 month visit. The change of UPDRS ranges from -70 to 20, larger value shows improvement of PD. (NCT02168842)
Timeframe: Baseline to 36 months of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Isradipine | -4.14 |
| Placebo (for Isradipine) | -4.41 |
Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the Systolic BP, Seated in the active treatment arm versus placebo between the baseline and 36 month visit. The change in Systolic BP, Seated ranges from -65 to 50. larger value shows worsening of conditions. (NCT02168842)
Timeframe: Baseline to 36 months of treatment
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Isradipine | -6.11 |
| Placebo (for Isradipine) | 1.03 |
Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the total (Part I-III) UPDRS score in the active treatment arm versus placebo between the baseline and 36 month visit. The change of UPDRS ranges from -30 to 80, larger value shows more disability from PD. (NCT02168842)
Timeframe: Baseline to 36 months of treatment
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Isradipine | 2.99 |
| Placebo (for Isradipine) | 3.26 |
Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the UPDRS Part II (ADL Function) in the active treatment arm versus placebo between the baseline and 36 month visit. The change in UPDRS Part II ranges from -12 to 19, larger value shows more disability from PD. (NCT02168842)
Timeframe: Baseline to 36 months of treatment
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Isradipine | 2.3 |
| Placebo (for Isradipine) | 2.5 |
Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the UPDRS Part III OFF rating in the active treatment arm versus placebo between the baseline and 36 month visit. The change in UPDRS Part III OFF ranges from -30 to 100, larger value shows more disability from PD. (NCT02168842)
Timeframe: Baseline to 36 months of treatment
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Isradipine | 4.60 |
| Placebo (for Isradipine) | 4.50 |
Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the UPDRS Part IV in the active treatment arm versus placebo between the baseline and 36 month visit. The change in UPDRS Part IV ranges from -10 to 10, larger value shows more disability from PD. (NCT02168842)
Timeframe: Baseline to 36 months of treatment
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Isradipine | 1.18 |
| Placebo (for Isradipine) | 1.07 |
Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the UPDRS PIGD Score in the active treatment arm versus placebo between the baseline and 36 month visit. The change in UPDRS PIGD Score ranges from -1 to 3, larger value shows worsening of conditions. (NCT02168842)
Timeframe: Baseline to 36 months of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Isradipine | 0.12 |
| Placebo (for Isradipine) | 0.10 |
Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the MDS-UPDRS nmEDL(Non-Motor Experiences of Daily Living) in the active treatment arm versus placebo between the baseline and 12 month visit. The change of UPDRS ranges from -22 to 23, larger value shows more disability from PD. (NCT02168842)
Timeframe: Baseline to 12 months of treatment
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Isradipine | 4.65 |
| Placebo (for Isradipine) | 5.3 |
Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the UPDRS Tremor Score in the active treatment arm versus placebo between the baseline and 36 month visit. The change in UPDRS Tremor Score ranges from -1 to 2, larger value shows worsening of conditions. (NCT02168842)
Timeframe: Baseline to 36 months of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Isradipine | 0.00 |
| Placebo (for Isradipine) | 0.01 |
Number of participants with need for Antiparkinsonian Therapy. (NCT02168842)
Timeframe: Baseline to 36 months of treatment
| Intervention | participants (Number) |
|---|---|
| Isradipine | 145 |
| Placebo (for Isradipine) | 147 |
Number of participants with need for Dyskinesia Therapy. (NCT02168842)
Timeframe: Baseline to 36 months of treatment
| Intervention | participants (Number) |
|---|---|
| Isradipine | 24 |
| Placebo (for Isradipine) | 19 |
Number of participants with need for Fluctuations Therapy. (NCT02168842)
Timeframe: Baseline to 36 months of treatment
| Intervention | participants (Number) |
|---|---|
| Isradipine | 57 |
| Placebo (for Isradipine) | 64 |
2 reviews available for isradipine and Disease Exacerbation
| Article | Year |
|---|---|
Calcium Channel Antagonists as Disease-Modifying Therapy for Parkinson's Disease: Therapeutic Rationale and Current Status.
Topics: Animals; Calcium Channel Blockers; Calcium Channels; Clinical Trials, Phase II as Topic; Clinical Tr | 2016 |
Calcium antagonists in the treatment of hypertension: special clinical considerations.
Topics: Angina Pectoris; Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; | 1996 |
4 trials available for isradipine and Disease Exacerbation
| Article | Year |
|---|---|
Isradipine Versus Placebo in Early Parkinson Disease: A Randomized Trial.
Topics: Antiparkinson Agents; Calcium Channel Blockers; Disability Evaluation; Disease Progression; Double-B | 2020 |
Isradipine plasma pharmacokinetics and exposure-response in early Parkinson's disease.
Topics: Aged; Calcium Channel Blockers; Disease Progression; Double-Blind Method; Female; Humans; Isradipine | 2021 |
Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial.
Topics: Aged; Antihypertensive Agents; Arteriosclerosis; Carotid Arteries; Diastole; Disease Progression; Di | 1996 |
A randomized and double-blind comparison of isradipine and spirapril as monotherapy and in combination on the decline in renal function in patients with chronic renal failure and hypertension.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel B | 2001 |
8 other studies available for isradipine and Disease Exacerbation
| Article | Year |
|---|---|
Re-Analysis of the STEADY-PD II Trial-Evidence for Slowing the Progression of Parkinson's Disease.
Topics: Clinical Trials as Topic; Disease Progression; Double-Blind Method; Humans; Isradipine; Mental Statu | 2022 |
A Clinical Trial of Isradipine: What Went Wrong?
Topics: Calcium Channel Blockers; Disability Evaluation; Disease Progression; Humans; Isradipine; Parkinson | 2020 |
Isradipine Versus Placebo in Early Parkinson Disease.
Topics: Antiparkinson Agents; Calcium Channel Blockers; Disability Evaluation; Disease Progression; Humans; | 2020 |
Isradipine attenuates MPTP-induced dopamine neuron degeneration by inhibiting up-regulation of L-type calcium channels and iron accumulation in the substantia nigra of mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biomarkers; Calcium Channel Blockers; Calcium | 2017 |
[Effects of therapy with various groups of antianginal agents on life quality of the elderly with coronary heart disease and comorbid depression].
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Atenolol; Calcium Channel Blockers; Depression; Dise | 2005 |
Intracellular redistribution of dihydropyridine receptor in the rat heart during the progression of sepsis.
Topics: Animals; Calcium Channels, L-Type; Disease Progression; Isradipine; Male; Myocardium; Phosphorylatio | 2007 |
Improved renal perfusion prevents disease progression in focal segmental glomerulosclerosis.
Topics: Cilazapril; Dipyridamole; Disease Progression; Glomerulosclerosis, Focal Segmental; Heparin; Humans; | 1995 |
Objectives of high blood pressure treatment: left ventricular hypertrophy, diastolic function, and coronary reserve.
Topics: Antihypertensive Agents; Arterioles; Bisoprolol; Blood Pressure; Coronary Circulation; Diastole; Dil | 1998 |